The Immunosuppressive Vanguard: New Treatments in Noninfectious Uveitis
For decades, the only way to stop severe, noninfectious uveitis (autoimmune inflammation inside the eye) was to blast the patient with massive doses of systemic corticosteroids, effectively destroying the inflammation but causing catastrophic side effects like osteoporosis, diabetes, and psychosis. New Treatments in Noninfectious Uveitis is a fiercely advanced, highly specialized manual detailing the biological revolution in ocular immunology. This volume provides the exact blueprints required to suppress the immune system without destroying the patient.
Mastering Biologic Therapy
The core philosophy of this text is targeted molecular blockade. The authors aggressively detail the transition to biologic agents. It dictates exactly how monoclonal antibodies (like Adalimumab/Humira) specifically bind to and neutralize Tumor Necrosis Factor-alpha (TNF-a), shutting down the inflammatory cascade at its source rather than using the “carpet bombing” approach of traditional steroids.
Navigating Local Sustained Delivery
The book provides a masterclass in localized immunosuppression. It dictates the exact clinical pathways for implantable technology. It rigorously covers the surgical insertion of fluocinolone acetonide implants (like Retisert or Yutiq), which are anchored inside the eye and slowly release microscopic doses of steroids over three years, treating the eye while completely sparing the rest of the body from systemic toxicity.
Frequently Asked Questions (FAQs)
Does this book cover infectious uveitis caused by bacteria or viruses?
No, its absolute, exclusive focus is on *noninfectious (autoimmune)* uveitis and the advanced immunosuppressive drugs required to treat it.
Who is the primary audience?
It is the absolute, mandatory definitive reference for Uveitis Specialists, Rheumatologists, and Retina Specialists.
